Y Intercept Hong Kong Ltd Increases Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)

Y Intercept Hong Kong Ltd boosted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 160.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,006 shares of the company's stock after purchasing an additional 22,183 shares during the period. Y Intercept Hong Kong Ltd's holdings in Denali Therapeutics were worth $734,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP increased its stake in shares of Denali Therapeutics by 9.2% during the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock valued at $312,491,000 after buying an additional 903,683 shares during the period. FMR LLC boosted its holdings in Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock valued at $228,128,000 after acquiring an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock valued at $109,223,000 after purchasing an additional 1,451,770 shares during the period. Principal Financial Group Inc. raised its holdings in Denali Therapeutics by 13.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after purchasing an additional 149,939 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of Denali Therapeutics by 14.5% in the 3rd quarter. Fisher Asset Management LLC now owns 547,331 shares of the company's stock worth $15,944,000 after purchasing an additional 69,223 shares during the period. Institutional investors own 92.92% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DNLI. Deutsche Bank Aktiengesellschaft started coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target on the stock. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a report on Tuesday, January 7th. Oppenheimer lowered their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday. The Goldman Sachs Group reduced their price target on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Finally, William Blair reissued an "outperform" rating on shares of Denali Therapeutics in a research report on Friday. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $37.77.

Denali Therapeutics Trading Up 6.3 %

Denali Therapeutics stock traded up $0.96 during trading on Tuesday, reaching $16.16. The company had a trading volume of 1,654,738 shares, compared to its average volume of 995,681. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -5.86 and a beta of 1.43. The firm's 50-day simple moving average is $21.17 and its 200 day simple moving average is $24.51. Denali Therapeutics Inc. has a 52 week low of $14.08 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Vicki L. Sato sold 3,080 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now owns 107,976 shares of the company's stock, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Steve E. Krognes sold 3,339 shares of the firm's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the sale, the director now directly owns 25,757 shares in the company, valued at approximately $536,003.17. This represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,940 shares of company stock worth $973,442. Company insiders own 7.90% of the company's stock.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.